Hyperosmotic intraventricular drug delivery of DV1 in the management of intracranial metastatic breast cancer in a mouse model. (April 2019)

• Record Type: Journal Article
• Authors: Krishnamurthy, Satish; Li, Jie; Bodman, Alexa; Zhang, Chaozai; Yang, Yilei; An, Jing
• Is Part Of: Journal of clinical neuroscience. Volume 62(2019)
• Page Start: 207
• Page End: 211
• Publication Date: 2019-04
• Subjects: Breast cancer -- Hyperosmotic therapy -- CXCR4 -- Brain metastasis -- Drug delivery; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2019.01.003
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: The blood brain barrier is a limiting factor to treating cerebral metastasis. Targeted delivery by convection enhanced therapy bypasses the blood brain barrier. Delivery of drugs in hyperosmotic solutions has a passive tumor targeting effect. Abstract: Advances in therapies for breast cancer with cerebral metastases has been slow, despite this being a common diagnosis, due to limited drug delivery by the blood brain barrier. Improvements in drug delivery for brain metastasis to target the metastases and bypass the blood brain barrier are necessary. In our study, we delivered an inhibitor of chemokine receptor 4 by convection enhanced delivery in a hyperosmotic solution to prevent brain metastasis in a mouse model of metastatic breast cancer. We found the inhibitor limited metastatic disease and more interestingly, the hyperosmotic solution targeted tumor tissue allowing for a higher accumulation of the therapy into tumor tissue. This finding has the potential to improve delivery of chemotherapeutic agents to brain metastases.